USA: Researchers have found in a recent observational study that patients with generalized pustular psoriasis (GPP) face a ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

LEO Pharma acquires global rights to Spevigo for $105M, boosting its dermatology pipeline and expanding access for patients ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

LEO is claiming global commercial rights to Spevigo for GPP but will also collaborate with Boehringer on potential follow-up ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Spesolimab (Spevigo) is available on the NHS as a possible treatment for generalised pustular psoriasis (GPP) flares in adults. It should only be used to treat: moderate to severe flares that have not ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults. Last reviewed: 18 June 2025 Next review: This guidance will be reviewed if there is ...

The rare form of psoriasis can lead to serious complications such as sepsis and heart failure Boehringer Ingelheim’s Spevigo (spesolimab) has been recommended by the National Institute for Health and ...